6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
=30 O
% O
) O
were O
diarrhea O
, O
hand-and-foot O
syndrome O
, O
nausea O
, O
vomiting O
, O
abdominal O
pain O
, O
fatigue/weakness O
, O
and O
hyperbilirubinemia O
. O

Other O
adverse O
reactions O
, O
including O
serious O
adverse O
reactions O
, O
have O
been O
reported O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Adjuvant O
Colon O
Cancer O
Table O
4 O
shows O
the O
adverse O
reactions O
occurring O
in O
> O
=5 O
% O
of O
patients O
from O
one O
phase O
3 O
trial O
in O
patients O
with O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
study O
medication O
and O
had O
at O
least O
one O
safety O
assessment O
. O

A O
total O
of O
995 O
patients O
were O
treated O
with O
1250 O
mg/m O
2 O
twice O
a O
day O
of O
XELODA O
administered O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
and O
974 O
patients O
were O
administered O
5-FU O
and O
leucovorin O
( O
20 O
mg/m O
2 O
leucovorin O
IV O
followed O
by O
425 O
mg/m O
2 O
IV O
bolus O
5-FU O
on O
days O
1-5 O
every O
28 O
days O
) O
. O

The O
median O
duration O
of O
treatment O
was O
164 O
days O
for O
capecitabine-treated O
patients O
and O
145 O
days O
for O
5-FU/LV-treated O
patients O
. O

A O
total O
of O
112 O
( O
11 O
% O
) O
and O
73 O
( O
7 O
% O
) O
capecitabine O
and O
5-FU/LV-treated O
patients O
, O
respectively O
, O
discontinued O
treatment O
because O
of O
adverse O
reactions O
. O

A O
total O
of O
18 O
deaths B-NonOSE_AE
due O
to O
all O
causes O
occurred O
either O
on O
study O
or O
within O
28 O
days O
of O
receiving O
study O
drug O
: O
8 O
( O
0.8 O
% O
) O
patients O
randomized O
to O
XELODA O
and O
10 O
( O
1.0 O
% O
) O
randomized O
to O
5-FU/LV O
. O

Table O
5 O
shows O
grade O
3/4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
=1 O
% O
of O
patients O
from O
one O
phase O
3 O
trial O
in O
patients O
with O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
study O
medication O
and O
had O
at O
least O
one O
safety O
assessment O
. O

Table O
4 O
Percent O
Incidence O
of O
Adverse O
Reactions O
Reported O
in O
> O
=5 O
% O
of O
Patients O
Treated O
With O
XELODA O
or O
5-FU/LV O
for O
Colon O
Cancer O
in O
the O
Adjuvant O
Setting O
( O
Safety O
Population O
) O
Adjuvant O
Treatment O
for O
Colon O
Cancer O
( O
N=1969 O
) O
XELODA O
( O
N=995 O
) O
5-FU/LV O
( O
N=974 O
) O
Body O
System/Adverse O
Event O
All O
Grades O
Grade O
3/4 O
All O
Grades O
Grade O
3/4 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
47 O
12 O
65 O
14 O
Nausea B-OSE_Labeled_AE
34 O
2 O
47 O
2 O
Stomatitis B-OSE_Labeled_AE
22 O
2 O
60 O
14 O
Vomiting B-OSE_Labeled_AE
15 O
2 O
21 O
2 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
14 O
3 O
16 O
2 O
Constipation B-OSE_Labeled_AE
9 O
- O
11 O
< O
1 O
Upper B-OSE_Labeled_AE
Abdominal I-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
7 O
< O
1 O
7 O
< O
1 O
Dyspepsia B-OSE_Labeled_AE
6 O
< O
1 O
5 O
- O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
60 O
17 O
9 O
< O
1 O
Alopecia B-OSE_Labeled_AE
6 O
- O
22 O
< O
1 O
Rash B-OSE_Labeled_AE
7 O
- O
8 O
- O
Erythema B-OSE_Labeled_AE
6 O
1 O
5 O
< O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
16 O
< O
1 O
16 O
1 O
Pyrexia B-OSE_Labeled_AE
7 O
< O
1 O
9 O
< O
1 O
Asthenia B-OSE_Labeled_AE
10 O
< O
1 O
10 O
1 O
Lethargy B-OSE_Labeled_AE
10 O
< O
1 O
9 O
< O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
6 O
< O
1 O
6 O
- O
Headache B-OSE_Labeled_AE
5 O
< O
1 O
6 O
< O
1 O
Dysgeusia B-OSE_Labeled_AE
6 O
- O
9 O
- O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
9 O
< O
1 O
11 O
< O
1 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Conjunctivitis B-OSE_Labeled_AE
5 O
< O
1 O
6 O
< O
1 O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
2 O
< O
1 O
8 O
5 O
Respiratory B-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
2 O
- O
5 O
- O
Table O
5 O
Percent O
Incidence O
of O
Grade O
3/4 O
Laboratory O
Abnormalities O
Reported O
in O
> O
=1 O
% O
of O
Patients O
Receiving O
XELODA O
Monotherapy O
for O
Adjuvant O
Treatment O
of O
Colon O
Cancer O
( O
Safety O
Population O
) O
Adverse O
Event O
XELODA O
( O
n=995 O
) O
Grade O
3/4 O
% O
IV O
5-FU/LV O
( O
n=974 O
) O
Grade O
3/4 O
% O
Increased B-OSE_Labeled_AE
ALAT I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
) O
1.6 O
0.6 O
Increased B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
1.1 O
0.7 O
Decreased B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
2.3 O
2.2 O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
1.0 O
1.2 O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
13.0 O
13.0 O
Decreased B-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
[ O
note O
: O
The O
incidence O
of O
grade O
3/4 O
white B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
was O
1.3 O
% O
in O
the O
XELODA O
arm O
and O
4.9 O
% O
in O
the O
IV O
5-FU/LV O
arm O
. O
] O

2.2 O
26.2 O
Decreased B-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
/granulocytes O
2.4 O
26.4 O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
1.0 O
0.7 O
Increased B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
[ O
note O
: O
It O
should O
be O
noted O
that O
grading O
was O
according O
to O
NCIC O
CTC O
Version O
1 O
( O
May O
, O
1994 O
) O
. O

In O
the O
NCIC-CTC O
Version O
1 O
, O
hyperbilirubinemia B-NonOSE_AE
grade O
3 O
indicates O
a O
bilirubin B-NonOSE_AE
value I-NonOSE_AE
of I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
to I-NonOSE_AE
3 I-NonOSE_AE
. I-NonOSE_AE
0 I-NonOSE_AE
* I-NonOSE_AE
upper I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
( I-NonOSE_AE
ULN I-NonOSE_AE
) I-NonOSE_AE
range I-NonOSE_AE
, O
and O
grade O
4 O
a O
value O
of O
> O
3.0 O
* O
ULN O
. O

The O
NCI O
CTC O
Version O
2 O
and O
above O
define O
a O
grade O
3 O
bilirubin B-NonOSE_AE
value I-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
. I-NonOSE_AE
0 I-NonOSE_AE
to I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
. I-NonOSE_AE
0 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
, O
and O
grade O
4 O
values O
> O
10.0 O
* O
ULN O
. O
] O

20 O
6.3 O
6.2 O
Metastatic O
Colorectal O
Cancer O
Monotherapy O
Table O
6 O
shows O
the O
adverse O
reactions O
occurring O
in O
> O
=5 O
% O
of O
patients O
from O
pooling O
the O
two O
phase O
3 O
trials O
in O
first O
line O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

A O
total O
of O
596 O
patients O
with O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
were O
treated O
with O
1250 O
mg/m O
2 O
twice O
a O
day O
of O
XELODA O
administered O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
and O
593 O
patients O
were O
administered O
5-FU O
and O
leucovorin O
in O
the O
Mayo O
regimen O
( O
20 O
mg/m O
2 O
leucovorin O
IV O
followed O
by O
425 O
mg/m O
2 O
IV O
bolus O
5-FU O
, O
on O
days O
1-5 O
, O
every O
28 O
days O
) O
. O

In O
the O
pooled O
colorectal O
database O
the O
median O
duration O
of O
treatment O
was O
139 O
days O
for O
capecitabine-treated O
patients O
and O
140 O
days O
for O
5-FU/LV-treated O
patients O
. O

A O
total O
of O
78 O
( O
13 O
% O
) O
and O
63 O
( O
11 O
% O
) O
capecitabine O
and O
5-FU/LV-treated O
patients O
, O
respectively O
, O
discontinued O
treatment O
because O
of O
adverse O
reactions/intercurrent O
illness O
. O

A O
total O
of O
82 O
deaths B-NonOSE_AE
due O
to O
all O
causes O
occurred O
either O
on O
study O
or O
within O
28 O
days O
of O
receiving O
study O
drug O
: O
50 O
( O
8.4 O
% O
) O
patients O
randomized O
to O
XELODA O
and O
32 O
( O
5.4 O
% O
) O
randomized O
to O
5-FU/LV O
. O

Table O
6 O
Pooled O
Phase O
3 O
Colorectal O
Trials O
: O
Percent O
Incidence O
of O
Adverse O
Reactions O
in O
> O
=5 O
% O
of O
Patients O
Adverse O
Event O
XELODA O
( O
n=596 O
) O
5-FU/LV O
( O
n=593 O
) O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
- O
Not O
observed O
NA O
= O
Not O
Applicable O
Number O
of O
Patients O
With O
> O
One O
Adverse O
Event O
96 O
52 O
9 O
94 O
45 O
9 O
Body O
System/Adverse O
Event O
GI B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
55 O
13 O
2 O
61 O
10 O
2 O
Nausea B-OSE_Labeled_AE
43 O
4 O
- O
51 O
3 O
< O
1 O
Vomiting B-OSE_Labeled_AE
27 O
4 O
< O
1 O
30 O
4 O
< O
1 O
Stomatitis B-OSE_Labeled_AE
25 O
2 O
< O
1 O
62 O
14 O
1 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
35 O
9 O
< O
1 O
31 O
5 O
- O
Gastrointestinal B-OSE_Labeled_AE
Motility I-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
10 O
< O
1 O
- O
7 O
< O
1 O
- O
Constipation B-OSE_Labeled_AE
14 O
1 O
< O
1 O
17 O
1 O
- O
Oral B-OSE_Labeled_AE
Discomfort I-OSE_Labeled_AE
10 O
- O
- O
10 O
- O
- O
Upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
Inflammatory I-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
8 O
< O
1 O
- O
10 O
1 O
- O
Gastrointestinal B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
6 O
1 O
< O
1 O
3 O
1 O
- O
Ileus B-OSE_Labeled_AE
6 O
4 O
1 O
5 O
2 O
1 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
54 O
17 O
NA O
6 O
1 O
NA O
Dermatitis B-OSE_Labeled_AE
27 O
1 O
- O
26 O
1 O
- O
Skin B-OSE_Labeled_AE
Discoloration I-OSE_Labeled_AE
7 O
< O
1 O
- O
5 O
- O
- O
Alopecia B-OSE_Labeled_AE
6 O
- O
- O
21 O
< O
1 O
- O
General B-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
Weakness B-OSE_Labeled_AE
42 O
4 O
- O
46 O
4 O
- O
Pyrexia B-OSE_Labeled_AE
18 O
1 O
- O
21 O
2 O
- O
Edema B-OSE_Labeled_AE
15 O
1 O
- O
9 O
1 O
- O
Pain B-OSE_Labeled_AE
12 O
1 O
- O
10 O
1 O
- O
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
6 O
1 O
- O
6 O
1 O
< O
1 O
Neurological B-NonOSE_AE
Peripheral B-OSE_Labeled_AE
Sensory I-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
10 O
- O
- O
4 O
- O
- O
Headache B-OSE_Labeled_AE
10 O
1 O
- O
7 O
- O
- O
Dizziness B-OSE_Labeled_AE
[ O
note O
: O
Excluding O
vertigo B-NonOSE_AE
] O
8 O
< O
1 O
- O
8 O
< O
1 O
- O
Insomnia B-OSE_Labeled_AE
7 O
- O
- O
7 O
- O
- O
Taste B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
6 O
1 O
- O
11 O
< O
1 O
1 O
Metabolism B-NonOSE_AE
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
26 O
3 O
< O
1 O
31 O
2 O
< O
1 O
Dehydration B-OSE_Labeled_AE
7 O
2 O
< O
1 O
8 O
3 O
1 O
Eye B-NonOSE_AE
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
13 O
- O
- O
10 O
< O
1 O
- O
Vision B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
5 O
- O
- O
2 O
- O
- O
Respiratory B-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
14 O
1 O
- O
10 O
< O
1 O
1 O
Cough B-OSE_Labeled_AE
7 O
< O
1 O
1 O
8 O
- O
- O
Pharyngeal B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
5 O
- O
- O
5 O
- O
- O
Epistaxis B-OSE_Labeled_AE
3 O
< O
1 O
- O
6 O
- O
- O
Sore B-OSE_Labeled_AE
Throat I-OSE_Labeled_AE
2 O
- O
- O
6 O
- O
- O
Musculoskeletal B-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
10 O
2 O
- O
9 O
< O
1 O
- O
Arthralgia B-OSE_Labeled_AE
8 O
1 O
- O
6 O
1 O
- O
Vascular B-NonOSE_AE
Venous B-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
8 O
3 O
< O
1 O
6 O
2 O
- O
Psychiatric B-NonOSE_AE
Mood B-OSE_Labeled_AE
Alteration I-OSE_Labeled_AE
5 O
- O
- O
6 O
< O
1 O
- O
Depression B-OSE_Labeled_AE
5 O
- O
- O
4 O
< O
1 O
- O
Infections B-NonOSE_AE
Viral O
5 O
< O
1 O
- O
5 O
< O
1 O
- O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
Anemia B-OSE_Labeled_AE
80 O
2 O
< O
1 O
79 O
1 O
< O
1 O
Neutropenia B-OSE_Labeled_AE
13 O
1 O
2 O
46 O
8 O
13 O
Hepatobiliary B-NonOSE_AE
Hyperbilirubinemia B-OSE_Labeled_AE
48 O
18 O
5 O
17 O
3 O
3 O
6.3 O
Breast O
Cancer O
In O
Combination O
with O
Docetaxel O
The O
following O
data O
are O
shown O
for O
the O
combination O
study O
with O
XELODA O
and O
docetaxel O
in O
patients O
with O
metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
Table O
7 O
and O
Table O
8 O
. O

In O
the O
XELODA O
and O
docetaxel O
combination O
arm O
the O
treatment O
was O
XELODA O
administered O
orally O
1250 O
mg/m O
2 O
twice O
daily O
as O
intermittent O
therapy O
( O
2 O
weeks O
of O
treatment O
followed O
by O
1 O
week O
without O
treatment O
) O
for O
at O
least O
6 O
weeks O
and O
docetaxel O
administered O
as O
a O
1-hour O
intravenous O
infusion O
at O
a O
dose O
of O
75 O
mg/m O
2 O
on O
the O
first O
day O
of O
each O
3-week O
cycle O
for O
at O
least O
6 O
weeks O
. O

In O
the O
monotherapy O
arm O
docetaxel O
was O
administered O
as O
a O
1-hour O
intravenous O
infusion O
at O
a O
dose O
of O
100 O
mg/m O
2 O
on O
the O
first O
day O
of O
each O
3-week O
cycle O
for O
at O
least O
6 O
weeks O
. O

The O
mean O
duration O
of O
treatment O
was O
129 O
days O
in O
the O
combination O
arm O
and O
98 O
days O
in O
the O
monotherapy O
arm O
. O

A O
total O
of O
66 O
patients O
( O
26 O
% O
) O
in O
the O
combination O
arm O
and O
49 O
( O
19 O
% O
) O
in O
the O
monotherapy O
arm O
withdrew O
from O
the O
study O
because O
of O
adverse O
reactions O
. O

The O
percentage O
of O
patients O
requiring O
dose O
reductions O
due O
to O
adverse O
reactions O
was O
65 O
% O
in O
the O
combination O
arm O
and O
36 O
% O
in O
the O
monotherapy O
arm O
. O

The O
percentage O
of O
patients O
requiring O
treatment O
interruptions O
due O
to O
adverse O
reactions O
in O
the O
combination O
arm O
was O
79 O
% O
. O

Treatment O
interruptions O
were O
part O
of O
the O
dose O
modification O
scheme O
for O
the O
combination O
therapy O
arm O
but O
not O
for O
the O
docetaxel O
monotherapy-treated O
patients O
. O

Table O
7 O
Percent O
Incidence O
of O
Adverse O
Events O
Considered O
Related O
or O
Unrelated O
to O
Treatment O
in O
> O
=5 O
% O
of O
Patients O
Participating O
in O
the O
XELODA O
and O
Docetaxel O
Combination O
vs O
Docetaxel O
Monotherapy O
Study O
Adverse O
Event O
XELODA O
1250 O
mg/m O
2 O
/bid O
With O
Docetaxel75 O
mg/m O
2 O
/3 O
weeks O
Docetaxel100 O
mg/m O
2 O
/3 O
weeks O
( O
n=251 O
) O
( O
n=255 O
) O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
- O
Not O
observed O
NA O
= O
Not O
Applicable O
Number O
of O
Patients O
With O
at O
Least O
One O
Adverse O
Event O
99 O
76.5 O
29.1 O
97 O
57.6 O
31.8 O
Body O
System/Adverse O
Event O
GI B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
67 O
14 O
< O
1 O
48 O
5 O
< O
1 O
Stomatitis B-OSE_Labeled_AE
67 O
17 O
< O
1 O
43 O
5 O
- O
Nausea B-OSE_Labeled_AE
45 O
7 O
- O
36 O
2 O
- O
Vomiting B-OSE_Labeled_AE
35 O
4 O
1 O
24 O
2 O
- O
Constipation B-OSE_Labeled_AE
20 O
2 O
- O
18 O
- O
- O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
30 O
< O
3 O
< O
1 O
24 O
2 O
- O
Dyspepsia B-OSE_Labeled_AE
14 O
- O
- O
8 O
1 O
- O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
6 O
< O
1 O
- O
5 O
- O
- O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
63 O
24 O
NA O
8 O
1 O
NA O
Alopecia B-OSE_Labeled_AE
41 O
6 O
- O
42 O
7 O
- O
Nail B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
14 O
2 O
- O
15 O
- O
- O
Dermatitis B-OSE_Labeled_AE
8 O
- O
- O
11 O
1 O
- O
Rash B-OSE_Labeled_AE
Erythematous I-OSE_Labeled_AE
9 O
< O
1 O
- O
5 O
- O
- O
Nail B-OSE_Labeled_AE
Discoloration I-OSE_Labeled_AE
6 O
- O
- O
4 O
< O
1 O
- O
Onycholysis B-OSE_Labeled_AE
5 O
1 O
- O
5 O
1 O
- O
Pruritus B-OSE_Labeled_AE
4 O
- O
- O
5 O
- O
- O
General B-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
28 O
2 O
- O
34 O
2 O
- O
Asthenia B-OSE_Labeled_AE
26 O
4 O
< O
1 O
25 O
6 O
- O
Fatigue B-OSE_Labeled_AE
22 O
4 O
- O
27 O
6 O
- O
Weakness B-OSE_Labeled_AE
16 O
2 O
- O
11 O
2 O
- O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
13 O
< O
1 O
- O
13 O
2 O
- O
Lethargy B-OSE_Labeled_AE
7 O
- O
- O
6 O
2 O
- O
Pain B-OSE_Labeled_AE
7 O
< O
1 O
- O
5 O
1 O
- O
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
( I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
) O
4 O
< O
1 O
- O
6 O
2 O
- O
Influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Illness I-OSE_Labeled_AE
5 O
- O
- O
5 O
- O
- O
Neurological B-NonOSE_AE
Taste B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
16 O
< O
1 O
- O
14 O
< O
1 O
- O
Headache B-OSE_Labeled_AE
15 O
3 O
- O
15 O
2 O
- O
Paresthesia B-OSE_Labeled_AE
12 O
< O
1 O
- O
16 O
1 O
- O
Dizziness B-OSE_Labeled_AE
12 O
- O
- O
8 O
< O
1 O
- O
Insomnia B-OSE_Labeled_AE
8 O
- O
- O
10 O
< O
1 O
- O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
6 O
- O
- O
10 O
1 O
- O
Hypoaesthesia B-OSE_Labeled_AE
4 O
< O
1 O
- O
8 O
< O
1 O
- O
Metabolism B-NonOSE_AE
Anorexia B-OSE_Labeled_AE
13 O
1 O
- O
11 O
< O
1 O
- O
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
10 O
- O
- O
5 O
- O
- O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
7 O
- O
- O
5 O
- O
- O
Dehydration B-OSE_Labeled_AE
10 O
2 O
- O
7 O
< O
1 O
< O
1 O
Eye B-NonOSE_AE
Lacrimation B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
12 O
- O
- O
7 O
< O
1 O
- O
Conjunctivitis B-OSE_Labeled_AE
5 O
- O
- O
4 O
- O
- O
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
5 O
- O
- O
1 O
- O
- O
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
15 O
2 O
- O
24 O
3 O
- O
Myalgia B-OSE_Labeled_AE
15 O
2 O
- O
25 O
2 O
- O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
12 O
< O
1 O
- O
11 O
3 O
- O
Bone B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
8 O
< O
1 O
- O
10 O
2 O
- O
Cardiac B-NonOSE_AE
Edema B-OSE_Labeled_AE
33 O
< O
2 O
- O
34 O
< O
3 O
1 O
Blood B-NonOSE_AE
Neutropenic B-OSE_Labeled_AE
Fever I-OSE_Labeled_AE
16 O
3 O
13 O
21 O
5 O
16 O
Respiratory B-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
14 O
2 O
< O
1 O
16 O
2 O
- O
Cough B-OSE_Labeled_AE
13 O
1 O
- O
22 O
< O
1 O
- O
Sore B-OSE_Labeled_AE
Throat I-OSE_Labeled_AE
12 O
2 O
- O
11 O
< O
1 O
- O
Epistaxis B-OSE_Labeled_AE
7 O
< O
1 O
- O
6 O
- O
- O
Rhinorrhea B-OSE_Labeled_AE
5 O
- O
- O
3 O
- O
- O
Pleural B-OSE_Labeled_AE
Effusion I-OSE_Labeled_AE
2 O
1 O
- O
7 O
4 O
- O
Infection B-NonOSE_AE
Oral B-OSE_Labeled_AE
Candidiasis I-OSE_Labeled_AE
7 O
< O
1 O
- O
8 O
< O
1 O
- O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
6 O
< O
1 O
- O
4 O
- O
- O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
4 O
- O
- O
5 O
1 O
- O
Vascular B-NonOSE_AE
Flushing B-OSE_Labeled_AE
5 O
- O
- O
5 O
- O
- O
Lymphoedema B-OSE_Labeled_AE
3 O
< O
1 O
- O
5 O
1 O
- O
Psychiatric B-NonOSE_AE
Depression B-OSE_Labeled_AE
5 O
- O
- O
5 O
1 O
- O
Table O
8 O
Percent O
of O
Patients O
With O
Laboratory O
Abnormalities O
Participating O
in O
the O
XELODA O
and O
Docetaxel O
Combination O
vs O
Docetaxel O
Monotherapy O
Study O
Adverse O
Event O
XELODA O
1250 O
mg/m O
2 O
/bid O
With O
Docetaxel75 O
mg/m O
2 O
/3 O
weeks O
Docetaxel100 O
mg/m O
2 O
/3 O
weeks O
( O
n=251 O
) O
( O
n=255 O
) O
Body O
System/Adverse O
Event O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Hematologic B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
91 O
37 O
24 O
88 O
42 O
33 O
Neutropenia B-OSE_Labeled_AE
/ O
Granulocytopenia B-OSE_Labeled_AE
86 O
20 O
49 O
87 O
10 O
66 O
Thrombocytopenia B-OSE_Labeled_AE
41 O
2 O
1 O
23 O
1 O
2 O
Anemia B-OSE_Labeled_AE
80 O
7 O
3 O
83 O
5 O
< O
1 O
Lymphocytopenia B-OSE_Labeled_AE
99 O
48 O
41 O
98 O
44 O
40 O
Hepatobiliary B-NonOSE_AE
Hyperbilirubinemia B-OSE_Labeled_AE
20 O
7 O
2 O
6 O
2 O
2 O
Monotherapy O
The O
following O
data O
are O
shown O
for O
the O
study O
in O
stage B-Not_AE_Candidate
IV I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
who O
received O
a O
dose O
of O
1250 O
mg/m O
2 O
administered O
twice O
daily O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
. O

The O
mean O
duration O
of O
treatment O
was O
114 O
days O
. O

A O
total O
of O
13 O
out O
of O
162 O
patients O
( O
8 O
% O
) O
discontinued O
treatment O
because O
of O
adverse O
reactions/intercurrent O
illness B-Not_AE_Candidate
. O

Table O
9 O
Percent O
Incidence O
of O
Adverse O
Reactions O
Considered O
Remotely O
, O
Possibly O
or O
Probably O
Related O
to O
Treatment O
in O
> O
=5 O
% O
of O
Patients O
Participating O
in O
the O
Single O
Arm O
Trial O
in O
Stage O
IV O
Breast O
Cancer O
Adverse O
Event O
Phase O
2 O
Trial O
in O
Stage O
IV O
Breast O
Cancer O
( O
n=162 O
) O
Body O
System/Adverse O
Event O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
- O
Not O
observed O
NA O
= O
Not O
Applicable O
GI B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
57 O
12 O
3 O
Nausea B-OSE_Labeled_AE
53 O
4 O
- O
Vomiting B-OSE_Labeled_AE
37 O
4 O
- O
Stomatitis B-OSE_Labeled_AE
24 O
7 O
- O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
20 O
4 O
- O
Constipation B-OSE_Labeled_AE
15 O
1 O
- O
Dyspepsia B-OSE_Labeled_AE
8 O
- O
- O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
57 O
11 O
NA O
Dermatitis B-OSE_Labeled_AE
37 O
1 O
- O
Nail B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
7 O
- O
- O
General B-NonOSE_AE
Fatigue B-OSE_Labeled_AE
41 O
8 O
- O
Pyrexia B-OSE_Labeled_AE
12 O
1 O
- O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
6 O
1 O
- O
Neurological B-NonOSE_AE
Paresthesia B-OSE_Labeled_AE
21 O
1 O
- O
Headache B-OSE_Labeled_AE
9 O
1 O
- O
Dizziness B-OSE_Labeled_AE
8 O
- O
- O
Insomnia B-OSE_Labeled_AE
8 O
- O
- O
Metabolism B-NonOSE_AE
Anorexia B-OSE_Labeled_AE
23 O
3 O
- O
Dehydration B-OSE_Labeled_AE
7 O
4 O
1 O
Eye B-NonOSE_AE
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
15 O
- O
- O
Musculoskeletal B-NonOSE_AE
Myalgia B-OSE_Labeled_AE
9 O
- O
- O
Cardiac B-NonOSE_AE
Edema B-OSE_Labeled_AE
9 O
1 O
- O
Blood B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
26 O
2 O
2 O
Thrombocytopenia B-OSE_Labeled_AE
24 O
3 O
1 O
Anemia B-OSE_Labeled_AE
72 O
3 O
1 O
Lymphopenia B-OSE_Labeled_AE
94 O
44 O
15 O
Hepatobiliary B-NonOSE_AE
Hyperbilirubinemia B-OSE_Labeled_AE
22 O
9 O
2 O
6.4 O
Clinically O
Relevant O
Adverse O
Events O
in O
< O
5 O
% O
of O
Patients O
Clinically O
relevant O
adverse O
events O
reported O
in O
< O
5 O
% O
of O
patients O
treated O
with O
XELODA O
either O
as O
monotherapy O
or O
in O
combination O
with O
docetaxel O
that O
were O
considered O
at O
least O
remotely O
related O
to O
treatment O
are O
shown O
below O
; O
occurrences O
of O
each O
grade O
3 O
and O
4 O
adverse O
event O
are O
provided O
in O
parentheses O
. O

Monotherapy O
( O
Metastatic O
Colorectal O
Cancer O
, O
Adjuvant O
Colorectal O
Cancer O
, O
Metastatic O
Breast O
Cancer O
) O
Gastrointestinal B-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
proctalgia B-OSE_Labeled_AE
, O
ascites B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
gastric B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
ileus B-OSE_Labeled_AE
( O
0.3 O
% O
) O
, O
toxic B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
intestine I-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
Skin B-NonOSE_AE
& I-NonOSE_AE
Subcutan I-NonOSE_AE
. O

: O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
sweating B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
skin B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
radiation B-OSE_Labeled_AE
recall I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
0.2 O
% O
) O
General B-NonOSE_AE
: O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hoarseness B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
difficulty B-OSE_Labeled_AE
in I-OSE_Labeled_AE
walking I-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
mass I-OSE_Labeled_AE
, O
collapse B-OSE_Labeled_AE
, O
fibrosis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hemorrhage B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
Neurological B-NonOSE_AE
: O
insomnia B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
tremor B-OSE_Labeled_AE
, O
dysphasia B-OSE_Labeled_AE
, O
encephalopathy B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
coordination I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
impaired B-OSE_Labeled_AE
balance I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
: O
increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
cachexia B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hypertriglyceridemia B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hypokalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
Eye B-NonOSE_AE
: O
conjunctivitis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
: O
cough B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
asthma B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
: O
tachycardia B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
bradycardia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
extrasystoles B-OSE_Labeled_AE
, O
myocarditis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
Infections B-NonOSE_AE
: O
laryngitis B-OSE_Labeled_AE
( O
1.0 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
bronchopneumonia B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
keratoconjunctivitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
( O
0.3 O
% O
) O
, O
fungal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
including O
candidiasis B-OSE_Labeled_AE
) O
( O
0.2 O
% O
) O
Musculoskeletal B-NonOSE_AE
: O
myalgia B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
arthritis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
Blood B-NonOSE_AE
& I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
leukopenia B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
coagulation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
idiopathic B-OSE_Labeled_AE
thrombocytopenia I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
1.0 O
% O
) O
, O
pancytopenia B-OSE_Labeled_AE
( O
0.1 O
% O
) O
Vascular B-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
lymphoedema B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
( O
0.1 O
% O
) O
Psychiatric B-NonOSE_AE
: O
depression B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
( O
0.1 O
% O
) O
Renal B-NonOSE_AE
: O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
0.6 O
% O
) O
Ear B-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
: O
hepatic B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hepatitis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
cholestatic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
Immune B-NonOSE_AE
System I-NonOSE_AE
: O
drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
( O
0.1 O
% O
) O
Postmarketing O
: O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
lacrimal B-OSE_Labeled_AE
duct I-OSE_Labeled_AE
stenosis I-OSE_Labeled_AE
, O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
dehydration B-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
outcome O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
, O
cutaneous B-OSE_Labeled_AE
lupus I-OSE_Labeled_AE
erythematosus I-OSE_Labeled_AE
, O
corneal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
including O
keratitis B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
, O
severe O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
and O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
, O
persistent O
or O
severe O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
can O
eventually O
lead O
to O
loss B-NonOSE_AE
of I-NonOSE_AE
fingerprints I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
XELODA O
In O
Combination O
With O
Docetaxel O
( O
Metastatic O
Breast O
Cancer O
) O
Gastrointestinal B-NonOSE_AE
: O
ileus B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
necrotizing B-OSE_Labeled_AE
enterocolitis I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
esophageal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hemorrhagic B-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
( O
0.8 O
% O
) O
Neurological B-NonOSE_AE
: O
ataxia B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
syncope B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
( O
0.8 O
% O
) O
, O
polyneuropathy B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
migraine O
( O
0.4 O
% O
) O
Cardiac B-NonOSE_AE
: O
supraventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
( O
0.4 O
% O
) O
Infection B-NonOSE_AE
: O
neutropenic B-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
( O
2.4 O
% O
) O
, O
sepsis B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
bronchopneumonia B-OSE_Labeled_AE
( O
0.4 O
% O
) O
Blood B-NonOSE_AE
& I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
agranulocytosis B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
prothrombin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
( O
0.4 O
% O
) O
Vascular B-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
venous B-OSE_Labeled_AE
phlebitis I-OSE_Labeled_AE
and O
thrombophlebitis B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
( O
0.8 O
% O
) O
Renal B-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.4 O
% O
) O
Hepatobiliary B-NonOSE_AE
: O
jaundice B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hepatic B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hepatotoxicity B-OSE_Labeled_AE
( O
0.4 O
% O
) O
Immune B-NonOSE_AE
System I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
( O
1.2 O
% O
) O

